KRAS status is associated with metabolic parameters in metastatic colorectal cancer according to primary tumour location

Tabuso, M., Christian, M. ORCID: 0000-0002-1616-4179, Kimani, P., Gopalakrishnan, K. and Arasaradnam, R., 2020. KRAS status is associated with metabolic parameters in metastatic colorectal cancer according to primary tumour location. Pathology and Oncology Research, 26, pp. 2537-2548. ISSN 1219-4956

1332994_a1777_Christian.pdf - Published version

Download (860kB) | Preview


Background: Colorectal cancer (CRC) is characterized by complex interplay between macroenvironmental factors and tumor microenvironment, leading to variable outcomes in CRC patients. To date, there is still a need to identify macroenvironment/microenvironment factors that could define subgroup of patients that would benefit from specific anti-cancer treatment in order to improve patient selection for individualized targeted-based therapy.

Aims: Aim of this study was to evaluate associations between metabolic parameters and KRAS status in metastatic CRC (mCRC) according to a new tumour site classification.

Methods: Retrospective data were extracted from a total of 201 patients diagnosed with mCRC between 2012 and 2017 extracted from an established CRC database at our tertiary institute. Clinical-pathological data, including age, gender, BMI, hypertension, diabetes, pre-CRC diagnosis serum lipid levels and KRAS status were recorded. Categorical characteristics were compared using chi-squared test. Continuous characteristics were compared using Mann-Whitney U test. Log rank test was used to compare hazards for survival. In all comparisons, a two-sided P value < 0.05 was considered statistically significant.

Results: Out of 201 patients, 170 patients with complete serum lipid profile were included in the analysis. In recto-sigmoid cancers there was a statistically significant association between high cholesterol:high-density lipoprotein (chol:HDL) ratio and KRAS mutation (OR 2.69, 95% CI 1.1-6.4, p=0,02). In non recto-sigmoid cancers, high cholesterol was associated with KRAS WT (OR 0.39, CI 0.15-0.97, p=0.04). In 22 patients with KRAS mutated recto-sigmoid cancer stage IV at diagnosis normal chol:HDL ratio was associated with a trend to better survival (p=0.06).

Conclusions: High chol:HDL ratio was significantly associated with KRAS mutated metastatic recto-sigmoid cancers. A subgoup of mCRC patients with KRAS mutated recto-sigmoid cancer may benefit from optimal lipid lowering treatment.

Item Type: Journal article
Publication Title: Pathology and Oncology Research
Creators: Tabuso, M., Christian, M., Kimani, P., Gopalakrishnan, K. and Arasaradnam, R.
Publisher: Springer
Date: October 2020
Volume: 26
ISSN: 1219-4956
Rights: © The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
Divisions: Schools > School of Science and Technology
Record created by: Jonathan Gallacher
Date Added: 18 Jun 2020 16:27
Last Modified: 26 Jul 2021 15:27

Actions (login required)

Edit View Edit View


Views per month over past year


Downloads per month over past year